Aptevo Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Aptevo Therapeutics has a total shareholder equity of $12.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.8M and $12.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$16.90m |
| Equity | US$12.22m |
| Total liabilities | US$12.62m |
| Total assets | US$24.84m |
Recent financial health updates
Recent updates
Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy
Sep 19Aptevo meets primary endpoint in early-stage trial for blood cancer therapy
May 26Aptevo: Positive Early Stage Data Makes This Highly Interesting
Dec 02Aptevo gets $50/share takeout offer from shareholder Tang
Nov 18Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake
Nov 09Aptevo sells off after clarifying complete response in early-stage study on lead drug
Nov 05Financial Position Analysis
Short Term Liabilities: APVO's short term assets ($19.1M) exceed its short term liabilities ($7.2M).
Long Term Liabilities: APVO's short term assets ($19.1M) exceed its long term liabilities ($5.4M).
Debt to Equity History and Analysis
Debt Level: APVO is debt free.
Reducing Debt: APVO has no debt compared to 5 years ago when its debt to equity ratio was 63.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APVO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: APVO has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 24.2% each year.